Generating destination analysis
Compass Direction
Earnings IntelligenceAI-Powered
Compass Score
Key Numbers
Market Cap
$14B
P/E
N/A
Revenue Growth
+15.0%
Gross Margin
N/A
ROE
N/A
About Exact Sciences
Listed on the NASDAQ, Exact Sciences operates as a mid-cap player in the healthcare sector, offering investors focused access to biotech and genomics growth drivers. Cancer screening pioneer with Cologuard and liquid biopsy development. With a $14B market capitalization and no current profitability, the business is characterized by consistent top-line gains, reporting +15% revenue change year-over-year.
Expert Coverage
Unlock Full EXAS Analysis
Expert analysis and coverage for Exact Sciences
Or unlock everything now with Compass, $9/moPrice & Technical Analysis
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
More in Biotech & Genomics
Beam Therapeutics
Base editing platform with differentiated gene-editing pipeline.
DexCom Inc.
Continuous glucose monitoring leader expanding beyond diabetes management.
Alnylam Pharmaceuticals
RNA interference therapeutics leader with approved treatments for rare diseases.
Recursion Pharmaceuticals
AI-driven drug discovery platform using machine learning to decode biology at scale.